Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 8/2019

01-08-2019 | Tuberculosis | Review Article

Newer Drugs for Tuberculosis Prevention and Treatment in Children

Author: Ben J. Marais

Published in: Indian Journal of Pediatrics | Issue 8/2019

Login to get access

Abstract

Children suffer a huge and often an unrecognized burden of tuberculosis (TB) in endemic countries like India. Better data have improved the visibility of childhood TB, but the establishment of functional TB prevention and treatment programs for children remains challenging. Barriers to TB prevention include: 1) non-implementation of existing guidelines, 2) perceived inability to rule out active TB with fear of creating drug resistance and 3) limited local guidance on the use of preventive therapy after close contact with drug resistant TB. Barriers to TB treatment include: 1) diagnostic challenges in resource-limited settings, 2) presentation to maternal and child health (MCH) services with poor linkage to the TB control program and 3) limited local guidance on the treatment of children with likely drug resistant TB. The authors provide an overview of newer drugs used for TB prevention and treatment in children. They discuss new options for the treatment of latent TB infection (LTBI) and new or repurposed drugs used in the treatment of children with multidrug resistant (MDR)-TB. The background information provided describes the benefits, risks and feasibility of various treatment options, which should assist treatment decisions until updated World Health Organization (WHO) guidance becomes available.
Literature
1.
2.
Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:285–95.
3.
4.
Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5:e898–906.CrossRefPubMedPubMedCentral
5.
Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383:1572–9.
6.
Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16:1193–201.CrossRefPubMed
7.
Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15:e1002591.
8.
Fox GJ, Dobler C, Marais BJ, Denholm J. Preventive therapy for latent tuberculosis infection – the promise and challenges. Int J Infect Dis. 2017;56:68–76.CrossRefPubMed
9.
Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935–43.PubMed
10.
Accinelli RA, Romero LR, García RF, Sánchez R. Sustained benefit of community-based tuberculosis interventions after 30 years. Am J Respir Crit Care Med. 2015;191:1202–3.CrossRefPubMed
11.
Marais BJ. Improving access to tuberculosis preventive therapy and treatment for children. Int J Infect Dis. 2017;56:122–5.CrossRefPubMed
12.
Perez-Velez CM, Roya-Pabon CL, Marais BJ. A systematic approach to diagnosing intra-thoracic tuberculosis in children. J Infect. 2017;74:S74–83.CrossRefPubMed
13.
14.
Hong Kong Chest Service. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong chest service/tuberculosis research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1992;145:36–41.CrossRef
15.
Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149:689–97.
16.
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545.
17.
Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440–53.
18.
Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454–63.
19.
Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670–6.CrossRefPubMed
20.
Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–22.
21.
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.
22.
Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30:1607–15.
23.
Villarino ME, Scott NA, Weis SE, et al; International maternal pediatric and adolescents AIDS Clinical Trials Group; tuberculosis trials consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247–55.
24.
Pease C, Hutton B, Yazdi F, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17:265.
25.
Johnson KT, Churchyard GJ, Sohn H, Dowdy DW. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. Clin Infect Dis. 2018;67:1072–8.CrossRefPubMed
26.
Jindani A, Harrison TS, Nunn AJ, et al. RIFAQUIN trial Team.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599–608.
27.
Becerra M, Appleton S, Franke M, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011;377:147–52.CrossRefPubMed
28.
Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Resp J. 2013;41:140–56.CrossRef
29.
Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Tuberc Lung Dis. 2014;18:912–8.
30.
Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109:765–71.CrossRefPubMed
31.
Harausz EP, Garcia-Prats AJ, Seddon JA, et al. Sentinel project on pediatric drug-resistant tuberculosis. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations. Am J Respir Crit Care Med. 2017;195:1300–10.
32.
Diacon AH, Pym A, Grobusch MP, et al; TMC207-C208 study group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723–32.
33.
34.
Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis: time to act. Lancet Respir Med. 2018;6:662–6.
35.
Lewis JM, Hine P, Walker J, et al. First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Eur Respir J. 2016;47:1581–4.
36.
Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58:6406–12.CrossRefPubMedPubMedCentral
37.
Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016;71:1037–40.
38.
Liu Y, Matsumoto M, Ishida H, et al. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis. 2018;111:20–30.
39.
40.
Lachâtre M, Rioux C, Dû DL, et al. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis. 2016;16:294.
41.
Tadolini M, Lingtsang RD, Tiberi S, et al. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J. 2016;48:1527–9.
42.
Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508–18.
43.
Garcia-Prats AJ, Rose PC, Hesseling AC, Schaaf HS. Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations. Tuberculosis. 2014;94:93–104.CrossRefPubMed
44.
Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized control study in China. Clin Infect Dis. 2015;60:1361–7.
45.
Kroger A, Pannikar V, Htoon MT, et al. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results. Tropical Med Int Health. 2008;13:594–602.
Metadata
Title
Newer Drugs for Tuberculosis Prevention and Treatment in Children
Author
Ben J. Marais
Publication date
01-08-2019
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 8/2019
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-018-02854-8

Other articles of this Issue 8/2019

Indian Journal of Pediatrics 8/2019 Go to the issue

Original Article

Clinico-etiological Profile and Developmental Status of Infants Aged 1–24 months with Epilepsy

Commentary

Tuberculosis Control: WHO Perspective and Guidelines

Correspondence

Cardiac Troponin-T as a Marker of Myocardial Dysfunction in Term Neonates with Perinatal Asphyxia: Correspondence

Scientific Letter

Sialidosis Type 1: Giant SSEP and Novel Mutation

Scientific Letter

Serum Albumin and C-Reactive Protein as Predictors of Adverse Outcomes in Critically Ill Children: A Prospective Observational Pilot Study

Announcement

Notice of Duplicate Publication